Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24913972 | 0.99 | DRD2 (0.57) | DRD2TDP1SIGMAR1MAOAMAOB | |
| SCHEMBL14873885 | 0.96 | DRD2 (0.55) | DRD2TDP1SIGMAR1MEN1KMT2A | |
| SCHEMBL22783652 | 0.93 | DRD2 (0.56) | DRD2TDP1SIGMAR1MEN1KMT2A | |
| SCHEMBL17805291 | 0.92 | DRD2 (0.52) | DRD2TDP1SIGMAR1MEN1KMT2A | |
| SCHEMBL25128846 | 0.91 | DRD2 (0.51) | DRD2TDP1SIGMAR1MEN1KMT2A | |
| SCHEMBL21465932 | 0.90 | DRD2 (0.53) | DRD2TDP1SIGMAR1MAOAMAOB | |
| SCHEMBL22783648 | 0.90 | DRD2 (0.52) | DRD2TDP1SIGMAR1MEN1KMT2A | |
| SCHEMBL513795 | 0.90 | MEN1 (0.55) | DRD2TDP1SIGMAR1MEN1KMT2A | |
| SCHEMBL31301221 | 0.88 | DRD2 (0.55) | DRD2TDP1SIGMAR1MEN1KMT2A | |
| SCHEMBL3524057 | 0.88 | DRD2 (0.66) | DRD2TDP1SIGMAR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-1789049-A4 | CYCLIC AMIDE AND ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1789049-A2 | CYCLIC AMIDE AND ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006023617-A2 | CYCLIC AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | HCN4, CACNA1B, SCN5A | DRD2 1834/4885TDP1 4390/4885SIGMAR1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.